Reply to J.M. Guinebretiere and L. Arnould et al-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to J.M. Guinebretiere and L. Arnould et al

Published:2009-06-01 Issue:16 Volume:27 Page:2734-2735
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Badve Sunil S.¹,Baehner Frederick L.²,Gray Robert P.³,Childs Barrett H.⁴,Maddala Tara⁵,Liu Mei-Lan⁵,Rowley Steve C.⁴,Shak Steven⁵,Perez Edith A.⁶,Shulman Lawrence J.⁷,Martino Silvana⁸,Davidson Nancy E.³,Sledge George W.³,Goldstein Lori J.³,Sparano Joseph A.³

Affiliation:

1. Indiana University, Bloomington, IN; Eastern Cooperative Oncology Group, Boston, MA

2. University of California, San Francisco, San Francisco; Genomic Health Inc, Redwood City, CA

3. Eastern Cooperative Oncology Group, Boston, MA

4. sanofi-aventis, Bridgewater, NJ

5. Genomic Health Inc, Redwood City, CA

6. North Central Cancer Treatment Group, Rochester, MN

7. Cancer and Acute Leukemia Group B, Chicago, IL

8. Southwest Oncology Group, Ann Arbor, MI

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.21.8685

Reference17 articles.

1. Cancer Is Heterogeneous

2. Is Immunohistochemistry Less Sensitive Than Quantitative Reverse Transcriptase Polymerase Chain Reaction for Hormone Receptor Status Determination in Breast Cancer?

3. Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory

4. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

5. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the use of OncotypeDX®as an additional treatment decision tool in early breast cancer;Expert Review of Anticancer Therapy;2013-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3